Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues….

Leary A, Cowan R, Chi D, Kehoe S, Nankivell M.

Am Soc Clin Oncol Educ Book. 2016;35:153-62. doi: 10.14694/EDBK_160624. Review.

2.

[Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].

Segev Y, Gemer O, Auslender R, Lavie O.

Harefuah. 2014 Sep;153(9):527-31, 558. Review. Hebrew.

PMID:
25417489
3.

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2016 Mar;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008. Epub 2016 Jan 9.

4.

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.

Luo Y, Lee M, Kim HS, Chung HH, Song YS.

Medicine (Baltimore). 2016 Sep;95(36):e4797. doi: 10.1097/MD.0000000000004797.

5.

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

Morrison J, Haldar K, Kehoe S, Lawrie TA.

Cochrane Database Syst Rev. 2012 Aug 15;(8):CD005343. doi: 10.1002/14651858.CD005343.pub3. Review.

6.

Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.

Rowland MR, Lesnock JL, Farris C, Kelley JL, Krivak TC.

Am J Obstet Gynecol. 2015 Jun;212(6):763.e1-8. doi: 10.1016/j.ajog.2015.01.053. Epub 2015 Jan 31.

PMID:
25644442
7.
8.

Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.

Timmermans M, Sonke GS, van Driel WJ, Lalisang RI, Ottevanger PB, de Kroon CD, Van de Vijver KK, van der Aa MA, Kruitwagen RF.

Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:98-102. doi: 10.1016/j.ejogrb.2018.02.029. Epub 2018 Mar 6.

PMID:
29525755
9.

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.

PMID:
21917306
10.

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.

Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.

Gynecol Oncol. 2013 Apr;129(1):63-8. doi: 10.1016/j.ygyno.2013.01.009. Epub 2013 Jan 18.

PMID:
23337490
11.

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.

Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.

Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.

PMID:
27916269
12.

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.

Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G.

Eur J Cancer. 2016 May;59:22-33. doi: 10.1016/j.ejca.2016.01.017. Epub 2016 Mar 19.

PMID:
26998845
13.

Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.

Loizzi V, Leone L, Camporeale A, Resta L, Selvaggi L, Cicinelli E, Cormio G.

Oncology. 2016;91(4):211-216. Epub 2016 Aug 3. Review.

PMID:
27487241
14.

Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.

Ghaemmaghami F, Karimi-Zarchi M, Modares-Gilani M, Mousavi A, Behtash N.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):719-24.

15.

Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.

Pepin K, Bregar A, Davis M, Melamed A, Hinchcliff E, Gockley A, Horowitz N, Del Carmen MG.

Gynecol Oncol. 2017 Dec;147(3):612-616. doi: 10.1016/j.ygyno.2017.09.028. Epub 2017 Oct 4.

PMID:
28988028
16.

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Zhang GN, Liu H, Huang JM, Wang L, Zhao JS, Li C, Mi K, Zhu Y, Cheng J, Zha X.

Gynecol Oncol. 2014 Mar;132(3):752-7. doi: 10.1016/j.ygyno.2014.01.028. Epub 2014 Jan 23.

PMID:
24463159
17.
18.

Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.

Taşkın S, Güngör M, Ortaç F, Öztuna D.

Arch Gynecol Obstet. 2013 Dec;288(6):1399-403. doi: 10.1007/s00404-013-2924-7. Epub 2013 Jun 18.

PMID:
23775264
19.

The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.

Nicklin JL, McGrath S, Tripcony L, Garrett A, Land R, Tang A, Perrin L, Chetty N, Jagasia N, Crandon AJ, Nascimento M, Walker G, Sanday K, Obermair A.

Aust N Z J Obstet Gynaecol. 2017 Dec;57(6):651-658. doi: 10.1111/ajo.12665. Epub 2017 Jul 18.

PMID:
28718942
20.

Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.

Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, Lau S, Gotlieb WH.

Gynecol Oncol. 2017 Mar;144(3):474-479. doi: 10.1016/j.ygyno.2016.12.017. Epub 2016 Dec 29.

PMID:
28041690

Supplemental Content

Support Center